Ignite Creation Date:
2024-05-06 @ 3:23 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02271139
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2017-03-09
First Post:
2014-10-17
Brief Title:
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer NSCLC After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Organization Data
Organization:
Genentech Inc
Class:
INDUSTRY
Study ID:
ML29453
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Genentech Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None